Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569769 | 0.89 | KDM4E (0.41) | FEN1ELANEMAPTTP53KDM4E | |
| SCHEMBL4569764 | 0.79 | KMT2A (0.45) | FEN1ELANEKDM4EALDH1A1MEN1 | |
| SCHEMBL13168783 | 0.76 | CCNT1 (0.47) | FEN1ELANEKDM4EALDH1A1PRKCB | |
| SCHEMBL4569770 | 0.74 | CYP19A1 (0.34) | — | |
| SCHEMBL18509150 | 0.74 | ELANE (0.40) | FEN1ELANECOMTKDM4EALDH1A1 | |
| SCHEMBL12146938 | 0.74 | ELANE (0.40) | FEN1ELANEMAPTTP53COMT | |
| SCHEMBL30902715 | 0.74 | ELANE (0.40) | FEN1ELANEMAPTCOMTKDM4E | |
| SCHEMBL29223650 | 0.74 | ELANE (0.40) | FEN1ELANEMAPTCOMTKDM4E | |
| SCHEMBL3210383 | 0.74 | ELANE (0.40) | FEN1ELANECOMTKDM4EALDH1A1 | |
| SCHEMBL18993226 | 0.73 | PDE4A (0.42) | FEN1ELANEKDM4EALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | FEN1 1354/4885ELANE 2008/4885MAPT 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.